Figure 2.Comparison of survival between FH-dRCC patients and T2 pRCC. (A) DFS of FH-dRCC and T2 pRCC; (B) CSS of FH-dRCC and T2 pRCC).
Figure 2 — The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma | Aging
